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A method is described and illustrated for calculating near optimal planned lifetime sched- 
ules of cervical smear examinations on an individual-by-individual basis. The method can 
be used to minimize the sum (discounted present value) of lifetime costs for prevention, 
management, treatment, and follow-up, plus the expected cost or loss if death occurs 
prematurely. A stochastic model of health, and of disease and death if they occur, is the 
basis of a computer program for finding the required examination ages. The program has 
built-in options of data and parameter values, which the user may override with preferred 
other values. The built-in data include estimates drawn from the British Columbia screening 
program, and, for loss due to death, from Social Security Administration data. Early 
cervical neoplasia is treated as being potentially nonprogressive to an extent that is un- 
predictable in the affected individual. Illustrations are presented of the comparative effects 
on optimal examination schedules, and on costs and return on preventive cytology regarded 
as an investment, of relatively low vs relatively high likelihood of disease onset occurring, 
of various levels of costs, including an effect of inflation, and of false-positive reports in 
cytology. 
I. INTRODUCTION 
Various investigators have made recommendations as to the age at which a 
female should have a first Pap-smear examination and how often she should have 
one thereafter. Gray has reviewed some of these recommendations [l] and we 
will not consider them here. Although the Pap test has been widely used in the 
belief that it is beneficial in the secondary prevention of cervical cancer, no 
significant trials have ever been mounted to evaluate it, and debate has continued 
as to its effectiveness. The probable benefit, and the frequencies for smear 
examinations that are needed to secure that benefit, have been estimated by 
taking what amount to hypothetical views about what happens when what the 
smear examination detects is, instead, undetected and untreated. 
It would appear that the best frequency plan might well differ, even signifi- 
cantly, from individual to individual. Considering the etiological evidence, in- 
dividuals could be expected to differ in their perc$ptions of their own risk levels 
for cervical cancer. The fact that knowledge about cervical neoplasia is still 
incomplete, that trends may be occurring in the likelihood of developing the 
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disease, and that new methods and criteria of diagnosis and of management are 
continuing to develop, can be expected to have different significance for different 
individuals. These, again, cannot be expected to have the same objectives, nor 
the same resources, for this preventive aspect of personal health, nor to have 
the same perception of the threat which cervical cancer poses to their bodies 
and lives, nor are they likely to be expecting to suffer the same loss if the disease 
does develop, nor to expect their survivors to suffer the same losses if they die 
from it prematurely. Yet these considerations all go into a rational individual 
decision as to how intense prevention to undertake. 
This report summarizes and illustrates briefly a computerized approach that 
has been developed with the aim of permitting factors and considerations of the 
above sort to be taken into account on an individualized basis and to calculate, 
for any healthy such individual (or category of such individuals) a planned sched- 
ule of ages for her successive smear examinations. The computer program has 
built-in default options for the input factors, but allows the user to override these 
with preferred other values. It produces approximately optimal schedules readily, 
so that the user can deliberately vary the inputs in multiple computer runs in 
order to observe how sensitive the resulting schedules are to possible unreliability 
of the input assumptions. The general approach is based upon a stochastic 
representation of health, cervical neoplasia and cancer, and death from other 
causes. It attempts to utilize views concerning the disease that are acceptable 
in gynecologic oncology. One optimal mode is straightforwardly actuarial, and 
might be developed into a basis for insurance against death from cervical cancer. 
The program produces data of potential epidemiological interest. 
II. PARAMETERS, DATA, AND METHODS 
The computer program offers as options certain baseline values for parameters 
and data sets, but the user can employ other values of his choosing. 
a. Disease, Detection and Behavior 
(I) Stochasticity. The program steps an individual through life in a stochastic 
fashion in 3-month time steps, starting with the individual at age 20 and healthy, 
and ceasing to follow healthy individuals at age 80. At each such step an outcome 
is assigned, e.g., for a healthy individual the outcome will be either to remain 
healthy, or to die of causes that have nothing to do with cervical cancer, or to 
develop an early phase of neoplastic disease. Outcomes are assigned randomly, 
in accordance with probabilities that can depend upon the age and state of the 
individual. Equivalently, the program may be thought of as stepping a large 
number of individuals who are identical as to age and state, with the number 
that are assigned to each outcome being that which is on the average expected 
in accordance with the associated probabilities. 
(2) Strains. For the illustrations presented below it is assumed that there are 
two significant kinds, or strains, of early neoplasia, of which any given individual 
can develop at most one. One strain, termed “progressive,” will sooner or later 
become invasive cancer in the affected individual if it is not treated. The other, 
termed “nonprogressive,” will never so progress. The program can be readily 
modified to provide for any number of strains each of which has an early phase 
S190 HERBERT P. GALLIHER 
and an invasive phase, or either alone, provided that strains are so defined that 
only a negligible number of individuals would develop more than one strain 
during life; computing time is proportional to the number of strains. 
(3) Biological onset. For each strain the user must select a rate of biological 
onset (probability of onset at each time step) of the early phase, which may be 
age specific. A built-in option follows the age distribution of the incidence rates 
of carcinoma in situ in followed individuals reported from the British Columbia 
program in 1968 [3]. Those rates are highest during the period from Ages 20 to 
35, declining progressively thereafter at a decreasing rate. In the illustrations 
below this same distribution has been used for both the progressive and the 
nonprogressive strain, but with different overall rates. In compiling Table 2 we 
observed that the total incidence rate of diagnoses of dysplasia was approximately 
54% of that for carcinoma in situ. In the illustrations the biological onset rate 
for the nonprogressive strain has been set at 54% of that for the progressive 
strain, at each age step. Onset rates can be entered by multiplying their age 
distributions by desired constants. In this way various levels of risk for the 
disease, or epidemiologically projected population rates, can be represented. 
Onset of an early phase is treated as being initially occult in the affected 
individual, with detection and diagnosis occurring, perhaps imperfectly, as de- 
scribed below. 
(4) False-positive results of examinations. When the effectiveness of scheduled 
cytology in preventing advanced cancer is being evaluated, any smear that is 
reported as abnormal and possibly signifying early neoplasia, but which in fact 
does not, functions as a “false-positive.” Varying degrees of follow-up are then 
required in order to rule disease out. In the computer program such developments 
do not become part of the history of an individual. The total average incidence 
rate in Table 1 is approximately 16.4 times that in Table 2. In the illustrations 
this ratio has been used, except as noted, at each age step at which preventive 
cytology is scheduled, to generate an expected complement of false-positive load 
for cytology. This load thus constitutes an involuntary additional investment in 
cytology. 
(5) Age-specific death rates from other causes. The program contains a built- 
in age-specific table of death rates from causes other than cervical cancer, which 
was developed from 1965 United States mortality data. An option allows the 
user to assign a multiplicative factor, e.g., risk level, for such death. 
(6) Probability distribution of the natural duration of early disease. The natural 
duration of early disease, i.e., its duration in the absence of detection or inter- 
vention, is assumed to be random in any affected individual. For each strain the 
program allows the user to specify a particular value for the average length of 
this duration. However, the form of the probability distribution of this duration 
is assigned to be the same for every strain, namely, that of the (negative) ex- 
ponential probability distribution. Thus the distribution is in each case completely 
determined simply by specifying the mean (average) duration. For example, 
suppose that the early phase of one strain is being used to represent carcinoma 
in situ. Then given that a represented individual has unsuspected carcinoma in 
situ at some point in time during her life, the probability, after a further duration 
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of time of length t, that this condition is still present and has not progressed to 
invasive disease in the interim, assuming that it has not been detected or treated 
in that interim, is equal to e-“‘. Here the mean duration is equal to l/v. 
For reference, the typical numerical implications of this particular distribution 
with a mean of 10 years are suggested by the following set of sample values: 
t (years) 0.5 1.0 2.0 5.0 10. 20. 30. 
e-” (%) 95 90 82 61 37 14 5 
Thus 5% of all cases would be postulated to progress within 6 months or less 
after onset, or after any stipulated point in time (and about 1% in a little over 
a month) while at the other extreme 5% would be capable of going for 30 years 
or more without progressing. The illustrations below all assume a lo-year mean 
duration for the progressive strain. 
In the program as it is presently constructed, it is assumed that the value of 
l/v is not affected by the age of the diseased individual. A strain which is such 
that early disease is never of the progressive sort is readily represented by setting 
the value of v equal to 0. In order to represent a strain which never presents 
itself (pathologically) as early disease, one simply sets the value of ‘v equal to 
a large number, so that, in effect, the mean duration of early disease is equal 
to 0. 
(7) Noncytological detection of early disease. Since the intent of the program 
when used in certain modes is to optimize cytology which has been previously 
scheduled, it is important to account for cases which are detected at other times, 
and such cases are referred to as having been noncytologically detected. For 
example, some complaint may have caused the individual to seek medical ex- 
amination at other than the time for a regularly scheduled cervical smear, as a 
result of which-albeit with the assistance of cytology-the disease was detected. 
The reason may be of any sort. The program assumes that such detection could 
only occur randomly, and independently of any specific influences. For a case 
which is in the early phase, and which is eligible for such detection for a time 
period of length t, it is thus assumed that the probability that such detection 
does not occur is equal to emb’. Here it is natural to consider the quantity b as 
being the “rate” at which such detection occurs. In the absence of all preventive 
cytology, the fraction of cases which would be detected noncytologically, if the 
numerical effects of the occurrence of death from other causes is ignored, is 
equal to bl(b + v). (We omit the mathematical argument, which is well known.) 
This may be used to set the numerical value of b in relation to the value being 
used for v. Note that the value of b is not affected by the frequency of scheduled 
smear examinations. Except as noted, in the illustrations below b has been taken 
to be equal to 0. 
(8) Invasive disease and its noncytological detection. For any strain that has 
an invasive phase, the program assumes that time is of the essence in detecting 
invasion if death is to be avoided. Thus invasive disease is assumed to be curable 
at its onset, but ultimately to convert to disease which at detection will (ret- 
rospectively) be found to be incurable. Once onset occurs, an ongoing compe- 
tition is thus assumed to be initiated between detection and such conversion. 
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Noncytological detection can now include classical “clinical” detection, viz., 
from signs and symptoms. Both noncytological detection and (virtual) conversion 
to incurable (fatal) disease are assumed to be events which occur randomly 
during time (if at all). The time rates at which these events tend to occur are 
taken to be constant and independent of the age and the history of the affected 
individual, but can differ from strain to strain. Thus, given that an individual 
unsuspectedly has the invasive phase of some strain at some point in time during 
her life, the probability, after a succeeding duration of time of length t during 
which cytological detection does not occur, that the condition has neither become 
incurable nor been noncytologically detected, is assumed to be of the exponential 
form e-“‘eeg’, where m is the time rate for conversion to fatal disease and g is 
the time rate for noncytological detection. Equivalently, for disease that is not 
subject to cytological detection, the quantity l/g is the average age of invasion 
(since onset) at noncytological detection, while l/m is its average age in unde- 
tected cases at the time that conversion to fatal disease occurs. 
The user may assign values to g and m. In the illustrations below we have 
used l/g = 3 f years. If cytological detection were not available-as was the 
case historically before the Papanicoulaou smear-then of detected cases the 
fraction that would be found to be curable would be equal to g/(g + m) if the 
numerical effects of intervening death from other causes is ignored (again we 
omit the mathematical argument). In the illustrations we have taken this to be 
equal to 54%, so that l/m becomes, roughly, 4 years. It must be kept in mind 
that these parameter values represent averages. For reference, the following 
table of sample values profiles the numerical implications of these particular 
assumptions (again ignoring the effect of death from other causes): 
Age of invasion since 
onset (years) 
Percentage not yet 
detected if no 
cytology (lOtIe-@) 
Percentage curable if 
detected at this 
age (IOOe-“‘) 
116 0.5 1.0 1.5 2. 3. 4. 5. 7. 10. 
95 85 72 61 51 37 26 19 10 4 
% 88 78 69 61 47 37 29 17 8 
(9) Compliance, false-negative rate. An individual may fail to show up for a 
scheduled cervical smear examination, or at such an examination disease which 
is present may fail to be detected. In either case disease can be missed. The 
program requires that a probability, the miss probability, be assigned a numerical 
value. This value is applied to each scheduled examination, regardless of the 
age or history of the individual examined. In the illustrations below we have 
assumed that the no-show probability is 20% and the false-negative rate is 15%, 
resulting in a miss probability of 1 - (O.S)(O.SS) = 32%. 
b. Costs 
(I) Inflation (deflation); discounting. While the program contains built-in es- 
timated cost values for use as “default” options, the user can prefer other values, 
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e.g., in higher-cost applications or when the cost of premature death would be 
much higher (or lower) than the approximate average for the United States. The 
present program assumes that all unit-cost values will vary historically, during 
the planning future, only in accordance with inflation (or deflation) at a constant 
time rate. Accordingly, input unit-cost values should be stated in current dollars, 
and in the illustrations below we have used estimated 1981 values. 
For cost optimizations the user must specify a postinflation discount factor, 
the value of which might vary considerably depending upon the application since 
its function is to reflect the available postinflation return on investment from 
alternative opportunities (personal, medical, economic). Note that the agewise 
increase in the rate of death from other causes provides an inherent biological 
discounting effect, at an increasing rate. Although the effect of discounting is 
to make the resulting calculations of optimal strategies be less sensitive to errors 
in input values and to invalidity of assumptions, this effect should be reduced 
by inflation and augmented by deflation. In Tables 3-6 we have used a postin- 
flation discount rate of 4%, primarily because the estimated U.S. values for cost 
of premature death were not available at a lower rate. 
(2) Cost of a cervical smear. This may vary widely depending upon the ap- 
plication. An excessive cost can make it cost optimal to forego preventive cy- 
tology entirely. For a smear obtained during a multiphasic physical examination 
this cost should include the proportionate share not only of the time for that 
part of the examination but for the patient’s indirect cost as well. In the illus- 
trations presented below we have used $9. 
(3) Costs of management, treatment, and follow-up. These should include 
indirect costs. For each phase of each strain the program requires that a cost 
value be specified which equals the discounted present value, at the time detection 
occurs, not only of treatment but for all follow-up of the individual from then 
on. The latter is because the computer model provides no further stochastic 
tracking of a detected individual, and because it is assumed that strains have 
been defined in such a way that no individual can develop more than one strain. 
Since the effect of postinflation discounting is to dampen the contribution from 
such later follow-up expenses, nominal values or rough estimates of these later 
costs may suffice, although the extent to which resulting errors may affect optimal 
strategies may be best assessed experimentally. 
In the illustrations below we have employed the following values in terms of 
1981 dollars, and these are built-in program options: 
Condition 
Average cost of management, 
treatment, and 
follow-up (discounted) 
Insignificant + smear $ 100 
Nonprogressive early disease 2,000 
Progressive early disease 3,000 
Curable invasive disease 5,500 
Incurable invasive disease 17,000 
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Since the modalities with which these conditions are treated varies considerably, 
obviously a single figure for cost has to be an average. 
(4) Costs due to premature death. Premature death is no doubt the outstanding 
threat posed by cervical cancer. No qualitative index of prematurity appears to 
have been established. But estimates of the cost, in terms of lost expected 
subsequent earnings, have been published by Cooper and Rice at the Social 
Security Administration, as of 1972, averaged for US. females [4]. Their esti- 
mates include the marketplace equivalent of housewifely duties, and are dis- 
counted present values assuming no inflation after death. Applying the 97% 
increase in the consumer price index that has occurred from 1972 through 1980, 
but without adjusting for any interim change that may have occurred in relative 
participation in the workforce by females, their estimates in the case of 4% 
discounting become: 
Age 
Present value of subsequent ex- 
petted earnings 












A smoothed version of this table is available in the computer program, together 
with the option to multiply all of the above values by a desired constant, e.g., 
to adjust for individuals whose projected incomes are expected to be significantly 
different from the U.S. average. The discount and inflation factors described 
earlier are applied to the above table values, but not to the earnings rates upon 
which the Cooper and Rice tables are based; for them, the 4% after-death dis- 
counting without inflation remains unadapted in our program. 
c. Optimization Procedure 
For a 20-year-old individual, a cost-optimal schedule of planned examination 
ages is one that minimizes the total discounted present value, at age 20, of all 
expected future costs. This total is the equivalent required reserve to be invested 
at age 20 at an interest rate equal to the discount rate, to meet such costs, a 
standard concept in financial maintenance planning. To find the exactly optimal 
ages is relatively easy, with a computer, using a mathematical technique known 
as dynamic programming, provided that the miss probability is zero. If the miss 
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probability is greater than zero, the task can become relatively expensive of 
computer time, since no simple mathematical method short of exhaustive search 
is known in that case. A limited such search routine is available within the 
computer program. It has not been used in the illustrations presented below, 
and the “required ages” given there assume that the miss probability is zero. 
However, for those schedules, the “total costs” in the tables are the correct 
ones when the assumed miss probability (e.g., 32%) is used in the calculations. 
The optimization can be started at any age with the individual known to be 
free of disease at that age. For all the illustrations below, this age has been taken 
to be 20 years. 
III. ILLUSTRATIONS AND DISCUSSION 
The rates in Tables 1 and 2 were compiled from histories of each of the 
individuals in the two birth cohorts who were seen in the British Columbia 
program during the years 1950-1969, being some 120,000 persons in all. The 
histories were made available to us on tape by the program’s investigators. In 
addition to containing the year and month of birth of the individual, each entry 
in her history was dated as to year and month and was either a report of a smear 
examination, a report of a pathological investigation, a report of treatment (by 
type), a report of death with cause as cervical cancer where known, or some 
TABLE 1 
INCIDENCE OF FIRST ABNORMAL SMEAR IN FOLLOWED INDIVIDUALS” 
Born 1914-1918 
Average Person- Rate per 






I 994 25.2 
55 39 1,147 15.7 
56 40 1,984 13.1 
57 41 3,044 8.5 
58 42 4,492 9.6 
59 43 6,758 8.4 
60 44 9,594 9.7 
61 45 13,388 9.3 
62 46 17,525 7.9 
63 47 21,294 9.1 
64 48 23,994 13.3 
65 49 26,016 9.9 
66 50 27,586 11.2 
67 51 28,534 15.8 
68 52 28,854 15.7 
69 53 28,584 19.4 
* In the British Columbia screening program. 
Born 1929-1933 
Average Person- Rate per 
age years 1000 
19 
20 




24 498 10.0 
25 930 9.7 
26 1,536 11.1 
27 2,416 7.3 
28 4,252 5.4 
29 6,859 8.2 
30 10,638 7.3 
31 16,072 8.0 
32 21,716 8.7 
33 26,566 12.9 
34 30,606 11.9 
35 33,939 13.3 
36 36,616 19.2 
37 38,158 21.0 
38 38,382 29.3 
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TABLE 2 
INCIDENCE OF DYSPLASIA OR STAGE 0 IN FOLLOWED INDIVIDUALS“ 
Year 
Born 1914-1918 Born 1929-1933 
Average Person- Rate per Average Person- Rate per 
age years 10,000 age years 10,000 






























































’ In the British Columbia screening program. 
combination of these. We wrote a computer program to process, from these 
histories, various “first-event” rates, by following individuals who were at risk 
for the event. The rates in Tables 1 and 2 were calculated assuming that the 
individuals at risk are still being followed after the last entry in their histories. 
During the 1950s the risk pool was too small to provide significant yearly rates. 
During the 1960s a marked increase is evident in rate with age and year of 
observation, for each birth cohort, as is also a difference between the two cohorts. 
By comparison, the age-specific incidence rates (per 10,000 person-years) for 
carcinoma in situ reported by Fidler et al. ([3], Table XI), when all women 
screened in the program in the years 1960-1966 are pooled, average between 
8.1 and 11.9 from ages 20 to 35, then decline progressively to about 2 by age 
75. 
It is not our task here to interpret the apparent trends in Tables 1 and 2, nor 
to extrapolate an estimated update of the rates to 1981 and beyond. What these 
data suggest is that it would appear to be of interest to include, in our illustrations, 
a range in the level of values of onset rate (and these can of course be expected 
to exceed observed incidence rates) that would be considered as representing 
an average level of risk for cervical cancer. We have selected three levels, 
corresponding to age-adjusted rates of onset (onsets per 10,000 person-years) of 
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any given application, of course, the appropriate rate might or might not fall 
within this range. 
Table 3 is an extract of the information that is routinely produced by a computer 
run. The best “life-plan number of exams” is found (by the program) by ex- 
amining each possible number, from 0, which represents no use of cytology at 
all, up to a number which is sufficiently large that the optimum number has been 
found. For brevity’s sake only selected values of the possible number of ex- 
aminations are included in the table. The “expected total cost” includes the 
amount invested in cytology, which is shown separately. The optimum plan is 
one that minimizes this total, which in this case is 22 examinations. For each 
planned number of examinations the reduction in the baseline total cost, namely 
that for no planned cytology, is shown, and in this case is 67% at the optimum. 
Cytology can be regarded as an investment, and the total return on it at the 
optimum is 760%. Although the “marginal” return on investment would normally 
be calculated by comparing, for example, 20 examinations with 19, we have 
calculated it from one row in the table to the next lower row; thus when the 
number of planned examinations is increased from 15 to 20, there is a 105% 
return on the additional investment in cytology. 
It can be seen that to achieve the optimum cost the 22 examinations should 
be done at about every 15 months to age 35, the interval lengthening gradually 
thereafter. By comparison, an annual examination is nearly as efficient, although 
the cytological workload is nearly double, at a not quite offsetting reduction in 
other costs, viz., a 17% marginal loss from the optimum, which is comparatively 
small. 
To save space only the principal features and results for the other two values 
of onset rate for the progressive strain are shown, in Table 4. For the lower 
rate, the maximal attainable return on cytology, as a percentage of the baseline, 
is now lower. The annual smear does not compare as favorably. If only one 
examination were to be done, it should be done at about the same age as in 
Table 3. For the higher onset rate, the optimal examination frequency is virtually 
an annual one. Discounting dampens the contribution of events of later years 
to present cost, so that it is not the examinations past the age of 70, say, that 
make the difference between the annual and the optimal plans in this case, but, 
rather, the other differences in their schedules. 
These tables illustrate that even if only one examination is done in a lifetime, 
the baseline burden will be reduced markedly if that examination is done at the 
right age. Similarly, a few well-timed examinations are very effective, and have 
large marginal incentives. The program permits one to schedule any given number 
of examinations so as to minimize the probability that invasive disease ever 
develops in the person at risk (whether it is ever detected or not). Table 5 shows 
plans for doing this. There can now be no optimum, since the more examinations 
the lower the probability (thus this type of information, while perhaps reassuring, 
is not sufficient for resolving competing medical priorities). From this table we 
see that so-called “unscreened” individuals, unless they have never had so much 
as one Pap smear done, may well show an incidence rate of invasive disease 
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with number of biological onsets, not (clinical) incidence, of invasion. Number 
of onsets has not been discounted, but cytological costs have. 
In the case of individuals whose income level is higher than the U.S. average, 
the cost of premature death could be higher than that used for Table 3. In Table 
6 are the results when this cost is assumed to be five times the national average, 
under the assumption that all other costs remain the same. The potential for 
cytology is now much greater. Optimal smear frequency, viz., every 9 months 
to age 35, is not proportionately greater. 
During the years that we have studied the subject of this paper, progressive 
inflation has repeatedly made it necessary to revise cost data tables upward. 
Severe inflation tends to create a current shortage of capital and to reduce the 
competitiveness of the return on other than the most critical or favorable in- 
vestments. If inflation is severe enough, the effective postinflation discount rate 
may even become negative. For Table 7 it has been assumed that this rate has 
been reduced to zero. Examination ages now tend to be later than those in Table 
3. The investment return from preventive cytology appears as having increased, 
as has the optimal cytological workload, although the attainable efficiency has 
dropped. To have inflation make profitable investments appear to be even more 
so can be an undesirable unbalancing effect. 
The various tables suggest how the conclusions from computer runs are sen- 
sitive to the values of certain of the input factors. The following additional 
observations are based upon other computer runs whose results are not presented 
in detail here. 
(1) If the cost of the smear examination were $15, in Table 3 the optimal early 
interval between scheduled examinations would increase to 18 months, with the 
optimal total number of examinations dropping to 18 and the optimal percentage 
gain dropping to 62%. Thus, there is a significant incentive for having the cost 
of the smear examination (the total cost) be as low as possible, including the 
fact that more disease will be prevented when cytology is then optimally utilized. 
In Table 6, had the examination cost been $30, with a comparable increase in 
false-positive costs, the optimal early interval would have increased to 15 months, 
with the total planned number of examinations decreasing to 26 and the optimal 
percentage gain decreasing to 78%. As is suggested by Table 3, the cost of the 
smear examination would have to approach toward $300 before the result would 
be that scheduled cytology would become unprofitable, yet presumably its at- 
tractiveness would have been lost long before that cost level had been reached. 
(2) The effect of the cost of resolving false positives is, it would seem, to 
increase the virtual cost of the smear examination itself. Doubling the false- 
positive rate, or its cost, increases the optimal early interexamination interval 
from 15 to 18 months, although still with 21 examinations in all being optimal, 
while the cytology cost is increased by about 33%. Had it been assumed, for 
Table 3, that the false-positive rate was zero, the age schedules would not have 
changed significantly, although the optimal total planned number of examinations 
would have decreased to 19 while the optimal percentage gain would increase 
to 72%. 
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false-negative rate can have a significant effect on percentage gains and returns, 
but a lesser effect on schedules, to judge from a few exploratory exhaustive 
searches that we have made. But when examinations are done fairly frequently, 
as is typically the case for the “optimal” plans in the tables, the effect can be 
expected to be relatively smaller, at least if, as is assumed, disease that is present 
is not more likely to be missed at subsequent examinations if it was missed on 
any one occasion. This is because, even with a miss probability of 32% per 
occasion, only 10% will have been missed after two scheduled examination times 
have passed, only 3.3% after three, and so on. The implications when such 
interexamination “independence” cannot be assumed have not been studied. 
Otherwise, when preventive cytology is optimally used, there would not appear 
to exist a marked incentive for having an examination technique that yielded a 
lower false-negative rate, nor for having a sharply greater show probability, than 
has been assumed. 
(4) In the case of Table 3, if it were assumed that 67% of early-phase disease 
is self-detectable (as defined above), the optimal total planned number of ex- 
aminations would not change significantly, nor the schedule for them, but the 
percentage gain at the optimum would drop to 60%. But were the self-detectable 
percentage to be as large as 85%, the optimal total planned number of exami- 
nations would decrease to 17, the early interval now being 18 months, with the 
baseline burden dropping to $844. More interesting in that case is the fact that 
total costs, at the optimum, would be $427 vs $479, viz., still roughly comparable. 
In a similar way the computer program can be used to develop answers to 
other questions, such as the effect on conclusions were the age distribution of 
onset rates different from what has been assumed in the above illustrations; or 
were the durations of early disease, or of curable invasion, or of undetected 
invasion, assumed to be quite different than has been assumed here; or, were 
alternative detection techniques to be posed for comparative evaluation; or were 
management costs to be significantly different from the values that have been 
used in the illustrations here. 
The general approach lends itself to studying alternative hypotheses, from 
those underlying the present program, as regards the nature of risk, the variety 
of disease, potential time shifts in onset rates, age specificity of the values of 
disease parameters, the degree of multidimensionality of onsets and of termi- 
nations of disease phases, the behavior of individuals at risk, and other aspects. 
IV. SUMMARY 
It has not been the objective of this paper to make recommendations as to 
when females should have Pap smear examinations. We have described a method 
that would appear to facilitate making this decision readily on an individualized 
basis while yet taking advantage of epidemiological information. The method has 
not been tested in such use. We have illustrated the results in the case of a few 
selected values of the required input information that should be of interest, 
including illustrating degrees to which the decision would be sensitive to the 
choice of the values assigned to various of the input factors. 
It seems to us that the promise of being able to make the decision on an 
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individual basis but in a formal manner that explicitly synthesizes the relevant 
factors and considerations, will increase the demand for the kind of epidemiol- 
ogical information that is needed for the process. 
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